Evaluated in >13,000 adult patients with CKD associated with T2D taking KERENDIA or placebo
KERENDIA has a generally well-tolerated safety profile23
Adverse reactions reported in ≥1% of patients taking KERENDIA and more commonly than placebo (pooled data from FIGARO-DKD and FIDELIO-DKD)1,23
Incidence of reproductive system and breast disorders was similar between KERENDIA and placebo, respectively1
Use in pregnancy: There are no available data on KERENDIA use in pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies have shown developmental toxicity at exposures about 4 times those expected in humans. The clinical significance of these findings is unclear.23
- Initiation of KERENDIA may cause an initial small decrease in eGFR that occurs within the first 4 weeks of starting therapy and then stabilizes. In a study that included patients with CKD associated with T2D, this decrease was reversible after treatment discontinuation23
- Initiation of KERENDIA may also cause a small increase in serum uric acid. This increase appears to attenuate over time23
In FIDELIO-DKD, SBP was measured as part of the laboratory parameter safety evaluation17
SBP changes from baseline at month 117,23
- In adult patients with CKD associated with T2D who were treated with KERENDIA, the mean SBP decreased by 3 mm Hg and the mean diastolic blood pressure decreased by 1 to 2 mm Hg at month 1, remaining stable thereafter23
Addition and modification of background antihypertensive treatment throughout the trial were permitted at the discretion of the investigators in line with local guideline recommendations if blood pressure was thought to be uncontrolled at any point during the trial.17
KERENDIA has not been studied for and is not indicated for the treatment of hypertension.23
*Mixed model exploratory analysis with covariate factors of treatment group, eGFR category, albuminuria type, treatment time and baseline value, and baseline value time.17
CKD=chronic kidney disease; eGFR=estimated glomerular filtration rate; LS=least-squares; SBP=systolic blood pressure; T2D=type 2 diabetes.
INDICATION:
KERENDIA is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS:
- Concomitant use with strong CYP3A4 inhibitors
- Patients with adrenal insufficiency
WARNINGS AND PRECAUTIONS:
Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5.0 mEq/L
Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium
MOST COMMON ADVERSE REACTIONS:
- From the pooled data of 2 placebo-controlled studies, the adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo were hyperkalemia (14% vs 6.9%), hypotension (4.6% vs 3.9%), and hyponatremia (1.3% vs 0.7%)
DRUG INTERACTIONS:
- Strong CYP3A4 Inhibitors: Concomitant use of KERENDIA with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juice
- Moderate and Weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either KERENDIA or the moderate or weak CYP3A4 inhibitor and adjust KERENDIA dosage as appropriate
- Strong and Moderate CYP3A4 Inducers: Avoid concomitant use of KERENDIA with strong or moderate CYP3A4 inducers
USE IN SPECIFIC POPULATIONS:
- Lactation: Avoid breastfeeding during treatment with KERENDIA and for 1 day after treatment
- Hepatic Impairment: Avoid use of KERENDIA in patients with severe hepatic impairment (Child Pugh C) and consider additional serum potassium monitoring with moderate hepatic impairment (Child Pugh B)
Please read the Prescribing Information for KERENDIA.
